MEDIUM confidence: 100% data completeness, but the composite (53) sits in the indecisive 30–70 range — strong-buy and short calls require a more decisive composite. What does confidence mean?
Technical context for active traders — derived from price, the 50/200-day moving averages, the 52-week range, and recent volume. Not part of the QScore.
Avg target $424 (last qtr, 12 analysts) → $440 (last mo, 3) (+3.8%).
Buy-rated share 64% → 65% over ~3 months (+2pp).
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Apr 2026 | $10.82 | $12.58 | +16.3% |
| Jan 2026 | $3.10 | $3.33 | +7.4% |
| Oct 2025 | $4.93 | $6.03 | +22.3% |
| Jul 2025 | $8.91 | $8.84 | -0.8% |
| Apr 2025 | $11.41 | $11.97 | +4.9% |
| Jan 2025 | $3.80 | $3.84 | +1.1% |
| Oct 2024 | $9.66 | $8.37 | -13.4% |
| Jul 2024 | $10.01 | $10.12 | +1.1% |
Net buyback (repurchases less issuance) ÷ market cap, plus trailing dividend yield.
Net insider -$875K over 180 days (1 open-market buys, 5 sells). Insider buying is the informative signal; routine selling is normal.
Short interest, days-to-cover, and institutional-ownership change require a data-plan upgrade (not yet available).
Forward-return IC, quintile spread & hit rate publish on /performance as the tracking panel accrues enough no-look-ahead history.
| Metric (USD) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $138.6B— | $156.6B+13.0% | $171.3B+9.4% | $176.8B+3.2% | $199.1B+12.6% |
| EPS (dil.) | $24.73— | $24.28-1.8% | $25.22+3.9% | $25.68+1.8% | $25.12-2.2% |
| Free Cash Flow | $7.3B— | $7.2B-0.4% | $6.8B-6.7% | $4.6B-32.7% | $3.2B-30.3% |
| Gross Margin | 26.0% | 25.5%-0.4pp | 27.4%+1.9pp | 27.9%+0.4pp | 25.6%-2.3pp |
| Operating Margin | 6.5% | 5.4%-1.1pp | 5.1%-0.3pp | 5.0%-0.1pp | 4.1%-1.0pp |
| Net Margin | 4.4% | 3.8%-0.6pp | 3.5%-0.3pp | 3.4%-0.1pp | 2.8%-0.5pp |
Absolute figures with year-over-year change. Margins show the level with the change in percentage points (pp). “n/m” = not meaningful (prior ≤ 0); ⚠ marks a large percentage off a small base — read the dollar figure.
Fama-French 5-factor (2×3) + Momentum, monthly OLS with Newey-West errors. Bars show signed factor betas; faded bars/figures aren't statistically significant.
The QScore of 53 for Elevance Health indicates a neutral outlook, driven by a relatively strong value profile, with a P/E of 16.5 and P/B of 1.9, and low volatility, as evidenced by a beta of 0.7. However, the stock's growth score is pulled down by negative EPS and free cash flow growth. Momentum scores are modestly positive, exhibiting strong recent price movement with a 35.5% return over the past three months, while profitability metrics are average, with an ROE near 12%.